SRTSNasdaqSurgical & Medical Instruments & ApparatusUS GAAP · USD

Sensus Healthcare, Inc.

Sensus Healthcare, Inc. is a U.S.-based medical device company focused on non-invasive treatment of non-melanoma skin cancer and post-surgical keloid scar prevention. Its core platform is superficial radiation therapy (SRT), delivered through the SRT-100, SRT-100+ and SRT-100 Vision systems, with operations run as a single segment from Boca Raton, Florida.

Kysy yhtiöstä
Liikevaihto27,5milj. USD
−34,3 %v/v
Liikevoitto (EBIT)−10,3milj. USD
−227,4 %v/v
EBIT-marginaali−37,5%
−56,9 %-yks.v/v
Nettotulos−7,7milj. USD
−216,1 %v/v
Vapaa kassavirta0,3milj. USD
+130,0 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−200204060milj. USD2020: 9,6 milj. USD2020: EBIT −8,2 milj. USD20202021: 27 milj. USD2021: EBIT 4,1 milj. USD20212022: 45 milj. USD2022: EBIT 15 milj. USD20222023: 24 milj. USD2023: EBIT −0,38 milj. USD20232024: 42 milj. USD2024: EBIT 8,1 milj. USD20242025: 27 milj. USD2025: EBIT −10 milj. USD202527−10
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Sensus Healthcare, Inc.

Liiketoiminta

Osuus liikevaihdosta
SRT treatment systems65 %

Superficial radiation therapy devices used to treat non-melanoma skin cancer and keloids.

Fair Deal Agreement20 %

Recurring revenue model where Sensus provides equipment and clinical support in exchange for a share of reimbursement.

Sentinel service program8 %

Maintenance and support contracts covering parts, labor, preventive maintenance, and installation-related services.

Consumables5 %

Disposable shielding, safety items, probe film, and applicator tips used with SRT treatments.

Other services and legacy products2 %

Operational healthcare services and limited legacy distribution of aesthetic laser devices.

Tuotteet

Raportoitu · osuus liikevaihdosta
71,9%12,6%9,2%FY2025100 %
  • Products71,9 %
  • Service Revenue12,6 %
  • Services9,2 %
  • Product Revenue6,3 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Sensus sells primarily to dermatology clinics, independent medical practices, and corporate accounts that treat skin cancer and related conditions. Its customer base also includes providers using the Fair Deal Agreement model, where Sensus supplies equipment and clinical support in exchange for reimbursement-linked economics. The company’s products are used by physicians and clinics that need a non-invasive alternative to surgery for selected skin lesions and keloid prevention.

Dermatology clinics

Buy SRT systems and services to treat non-melanoma skin cancer and keloids in outpatient settings.

Independent medical practices

Purchase systems or use financing/service models to add a reimbursable skin-treatment capability.

Corporate accounts

Acquire multiple systems or standardized service packages across clinic networks.

Fair Deal Agreement users

Access SRT through a revenue-share arrangement rather than an upfront purchase.

Existing installed-base customers

Buy consumables, maintenance, and support to keep installed systems operating.

Strategia

Sensus is focused on expanding adoption of its SRT platform through reimbursement support, direct sales, and service-based commercial models. It is also building adjacent offerings such as financing, cloud connectivity, and operational support to reduce adoption friction and deepen the installed base relationship. These priorities are intended to strengthen utilization of the platform and broaden access for clinics that prefer lower upfront commitment.

Expand reimbursement-supported adoptionLyhyt aikaväli

Coverage and reimbursement are central to physician and clinic willingness to use SRT.

Grow recurring and service-linked revenueKeskipitkä aikaväli

Service contracts and revenue-share models can stabilize customer relationships and improve retention.

Reduce purchase frictionLyhyt aikaväli

Financing and leasing alternatives can convert prospects that are sensitive to upfront capital cost.

Increase installed-base utilityKeskipitkä aikaväli

Software and connectivity can make existing systems more valuable and support repeat usage.

Maantiede

Q1/2026

Sensus operates globally but is heavily concentrated in the United States, which accounted for 92% of sales in 2025 and 96% in 2024. The company also has installed systems in 21 countries, giving it a small international footprint relative to its U.S. base. This concentration makes reimbursement, customer purchasing patterns, and provider adoption in the U.S. especially important to results.

USA75 %
Kina25 %

Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.

Riskit

Sensus is exposed to reimbursement risk because demand for its procedures depends on coverage and payment levels from Medicare, Medicaid, and private insurers. The business is also concentrated in the U.S. and with a small number of customers, so changes in purchasing patterns, competitive products, or the loss of a major account can materially affect revenue. As a medical device company, it also faces regulatory, litigation, supplier, and product adoption risks typical of the industry.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Customer concentration1Geographic concentration2Third-party reimbursement risk3Single-source supplier dependence4Regulatory and litigation risk5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Customer concentrationVaikutus: KriittinenTodennäköisyys: Korkea

    A single U.S. customer accounted for a large share of revenue, making results volatile.

    Kohdistuu: Historically largest customer

  2. Geographic concentrationVaikutus: KorkeaTodennäköisyys: Korkea

    Most sales come from the U.S., so domestic demand shifts have outsized impact.

    Kohdistuu: United States

  3. Third-party reimbursement riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Physicians and clinics may not adopt SRT if payors do not cover procedures adequately.

    KohdistuuU.S. MedicareMedicaidPrivate insurers
  4. Single-source supplier dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The company relies on a preferred supplier for x-ray tubes and other major components.

    Kohdistuu: Key components for SRT systems

  5. Regulatory and litigation riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Medical device companies face FDA oversight, enforcement, and patent disputes.

    Kohdistuu: Class II devices and skin cancer treatment market

Kysy Clarifolta: Sensus Healthcare, Inc.

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition

The company sells systems, service programs, consumables, and reimbursement-linked arrangements with different recognition patterns.

Vaikutus: Can shift revenue between periods and affect comparability

Fair Deal Agreement accounting

Revenue-share economics and bundled services require judgment on contract accounting and timing.

Vaikutus: Affects reported revenue mix and margin profile

Deferred revenue and service obligations

Sentinel and other support programs are recognized over time as services are delivered.

Vaikutus: Impacts balance sheet liabilities and future revenue recognition

Income tax estimates and credits

Management noted estimated tax credits affecting the effective tax rate.

Vaikutus: Can cause volatility in tax expense and net income

Inventory and supply chain commitments

Advance ordering is used to manage inflation and component availability.

Vaikutus: Can affect working capital and inventory valuation

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Senseonics Holdings, Inc.

SENS · Industrial Instruments For Measurement, Display, and Control

Spectral AI, Inc.

MDAIW · Surgical & Medical Instruments & Apparatus

STRATA Skin Sciences, Inc.

SSKN · Surgical & Medical Instruments & Apparatus

Senzime

SEZI · Health Care

Profound Medical Corp.

PROF · Surgical & Medical Instruments & Apparatus

Lantheus Holdings, Inc.

LNTH · In Vitro & In Vivo Diagnostic Substances

Päivitetty: 24.9.2026

Sensus Healthcare, Inc. (SRTS) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo